Midkine Conference - 2010 Program

Thursday 4th November

09:45am - 11:00am SESSION 1: Welcome and first plenary


09:45am - 10:00am

Welcome and Introduction
Maria Halasz, CEO, Cellmid Ltd, Sydney, Australia

10:00am - 11:00am

Midkine: A small protein with a big hope

Dr Takashi Muramatsu, Aichi Gakuin University, Aichi, Japan

11:00am - 11:30am

Morning tea and poster session


11:30am - 12:45pm SESSION 2: Midkine as a disease biomarker


11:30am - 12:00pm

Midkine as a cancer biomarker
Darren Jones, Head of Product Development, Cellmid Ltd, Sydney, Australia

12:00pm - 12.30pm

Development of a validated MK ELISA on behalf of Cellmid
Dr Kathrin Guenther, Director International Marketing, Biogenes GmbH, Berlin, Germany

12:30pm - 12:45pm

Product Launch: Cellmid’s validated MK ELISA
Maria Halasz, CEO, Cellmid Ltd, Sydney, Australia

12:45pm -1:45pm



1:45pm -12:45pm SESSION 3: Novel therapeutic applications for MK


1:45pm - 2:15pm

Antibacterial and antifungal activity of MK and PTN
Dr Sara Svensson, Lund University Hospital, Lund, Sweden

2:15pm - 2:45pm

Induction of CD8 and CD4 T cell responses specific for the tumor antigen MK
Dr Bernard Maillere, Institute of Biology and Technologies, SIMOPRO, Gif-sur-Yvette, France

2:45pm - 3:30pm

Afternoon tea and poster viewing


3:30pm - 4:30pm SESSION 4: Patenting and commercial considerations


3:30pm - 4:00pm

Building patent protection around midkine
Dr Jenny Petering, Partner, FB Rice & Co, Melbourne, Australia

4:00pm - 4:30pm

General discussion of patenting & IP protection

6:00pm - 8:00pm Welcome cocktail reception, Bungalow 8, King St Wharf

Thursday 5th November

10:00am-11:15am SESSION 5: Introduction to Day 2 and second plenary


10:00am - 10:15am

Introduction to Day 2
Darren Jones, Head of Product Development, Cellmid Ltd

10:15am - 11:15am

Midkine: An enigmatic but interesting growth factor
Dr Kenji Kadomatsu, Nagoya University Graduate School of Medicine, Nagoya, Japan

11:15am - 11:15am

Morning tea and poster session


11:45am - 12:15pm SESSION 6: The Zebrafish- a powerful model to understand MK biology


11:45am - 12:15pm

Midkine function in the developing nervous system of zebrafish
Dr Christoph Winkler, Dept of Biological Sciences, National University of Singapore, Singapore

12:15pm - 12:45pm

Expression and function of midkines in the zebrafish retina
Dr Peter Hitchcock, Dept of Ophthalmology and Visual Sciences, University of Michigan, USA

12:45pm -1:45pm



1:45pm -3:15pm SESSION 7: Targeting MK- new treatment opportunities


1:45pm - 2:15pm

New roles of MK in modulating morphine-induced analgesia
Dr Gonzalo Herradon, University San Pablo CEU, Spain

2:15pm - 2:45pm

Glioblastoma MK correlates with treatment failure of Glivec in combination with Roscovitine and indomethicine
Dr Mine Erguven,Yeni Yuzyil University, Istanbul, Turkey

2:45pm - 3:15pm

Suppression of hepatocellular carcinoma growth by MK antisense oligonucleotide nanoliposomes
Dr Dai Licheng, Huzhou Central Hospital, Huzhou, China

3:15pm - 3:45pm

Afternoon tea and poster viewing


3:45pm - 4:45pm SESSION 8: Midkine in Brain and Heart Infarction


3:45pm - 4:15pm

Protective effects of MK gene transfer in brain infarction
Dr Hiroaki Ooboshi, Fukuoka Medical & Dental Hospital, Fukuoka, Japan

4:15pm - 4:45pm

A preclinical program for MK protein to treat AMI
Dr Peter Ferdinandy, CEO, Pharmahungary, Szeged, Hungary

4:45pm - 5:00pm

Closing remarks and general discussion

7:00pm - 11:00pm Conference dinner, Nick’s Bar & Grill, King St Wharf

Saturday 6th November

10:00am - 2:00pm Sydney Harbour Cruise, departs King St Wharf (wharf 9)